Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

118.60 +5.23 (+4.61%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
40 41 Next >
Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks
Earnings have served to mitigate early January's weakness, and sentiment appears to be upbeat going into Wednesday's session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Investor Optimism Improves Following Earnings Reports; S&P 500 Reaches Another High
The CNN Money Fear and Greed index showed a further increase in overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks closed mixed on Tuesday, with the Dow... 
Via Benzinga
Topics Stocks
Exposures US Equities
Netflix, Tesla And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Earnings Preview For Abbott Laboratories
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today
Via Benzinga
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Earnings Scheduled For January 24, 2024
Companies Reporting Before The Bell • Freeport-McMoRan (NYSE:FCX) is estimated to report quarterly earnings at $0.22 per share on revenue of $5.86 billion. 
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss Abbott Laboratories Stock
Via Benzinga
Could Abbott Laboratories Stock Help You Become a Millionaire?
There is a lot going the company's way, despite recent struggles. 
Via The Motley Fool
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth. 
Via Benzinga
7 Safe-Haven Stocks to Protect Your Portfolio During a Recession
We may not be out of the woods yet, which means certain stable enterprises should be on your radar. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Johnson & Johnson's stock price is at a critical turning point
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Top Stocks To Watch As Earnings Approach
Several expansive companies are expected to post stellar quarterly growth when they report Q4 earnings on Wednesday, January 24. Here are a few top-rated stocks to consider as their quarterly results... 
Via Talk Markets
S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday?
US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,... 
Via Benzinga
Topics Stocks
Exposures US Equities
Tesla, Netflix, Intel Take Center Stage In Pivotal Q4 Earnings Week As S&P 500 Eyes Breaking New Highs
According to Factset, the fourth-quarter earnings season has had a weak start, with the percentage of S&P 500 companies reporting positive earnings surprises below average. 
Via Benzinga
Topics Stocks
Exposures US Equities
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
These stocks may help you win in 2024 -- no matter what the market does. 
Via The Motley Fool
Medtronic receives FDA approval for deep brain stimulation system
Medical device maker Medtronic PLC (NYSE: MDT) received U.S. FDA approval for its implantable medical device called the Percept PC Deep Brain Stimulation (DBS) 
Via MarketBeat
Exposures Product Safety
Better Growth Stock: Abbott vs. AbbVie
These healthcare giants also offer investors the promise of increasing passive income. 
Via The Motley Fool
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda 
Via Benzinga
3 Dividend Kings For Yield And Growth
Dividend Kings are known for safe dividends and reliable long-term growth. 
Via Talk Markets
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
Strong advantages over the competition could allow these businesses to keep raising their dividend payouts for at least another 10 years. 
Via The Motley Fool
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
From Tandem Diabetes Care, Inc.
Via Business Wire
3 Top Dividend Growth Stocks to Buy in 2024
Income investors should love these great stocks. 
Via The Motley Fool
Eli Lilly, Johnson & Johnson And Other Health Care Stocks From Wall Street's Most Accurate Analysts
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes... 
Via Benzinga
Silver Economy Successes: 3 Stocks Benefitting From an Aging Population
Explore our in-depth analysis of aging population stocks, uncovering the opportunities and challenges in this sector. 
Via InvestorPlace
Topics Economy
Exposures Economy
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
5 Top Stocks to Buy With Your End-of-the-Year Bonus
Your bonus could become the gift that keeps on giving. 
Via The Motley Fool
Better Growth Stock: AbbVie vs. Abbott Laboratories
Do Humira's declining sales give Abbott Laboratories the edge as the better growth stock? 
Via The Motley Fool
Dividend Income Update For November 2023
It’s dividend income update time. This is one of my favorite times of the month, as I get to review the previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.